%0 Journal Article
%A Ferdinandus, Justin
%A Kaul, Helen
%A Fosså, Alexander
%A Hüttmann, Andreas
%A Keil, Felix
%A Ko, Yon-Dschun
%A Hitz, Felicitas
%A Schwarz, Michaela
%A Trenker, Corinna
%A Kerkhoff, Andrea
%A Staib, Peter
%A Wille, Kai
%A Dresel, Irmgard
%A Hahn, Dennis
%A Hertenstein, Bernd
%A Moosmann, Peter
%A Mey, Ulrich
%A Balabanov, Stefan
%A Armytage, Tasman
%A Roncolato, Fernando
%A Hellmuth, Johannes C
%A Hertzberg, Mark
%A Kobe, Carsten
%A Klapper, Wolfram
%A Baues, Christian
%A Eich, Hans-Theodor
%A Kreissl, Stefanie
%A Fuchs, Michael
%A Jablonski, Janina
%A Schneider, Gundolf
%A Tharmaseelan, Hishan
%A Eichenauer, Dennis A
%A von Tresckow, Bastian
%A Borchmann, Peter
%A Bröckelmann, Paul J
%T Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.
%J Journal of clinical oncology
%V nn
%@ 0732-183X
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DKFZ-2025-01445
%P nn
%D 2025
%Z epub
%X Positron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effective in younger patients with advanced-stage classic Hodgkin lymphoma (AS-cHL). We report feasibility and efficacy of PET-guided BrECADD as first-line treatment in older patients with AS-cHL.Patients with AS-cHL aged 61-75 years were enrolled in a phase II single-arm cohort of the HD21 trial (ClinicalTrials.gov identifier: NCT02661503). Patients with negative PET/computed tomography after 2×BrECADD (PET2) received a total of 4×BrECADD, while PET2-positive patients received 6×BrECADD. The primary end point was the centrally reviewed complete remission (CR) rate after the end of chemotherapy (EOC). Secondary end points included feasibility, adverse events, treatment-related morbidity (TRMB), progression-free survival (PFS), overall survival (OS), and health-related quality of life (HRQoL).Between June 2020 and April 2023, 85 patients were enrolled, of whom 83 with a median age of 67 years (range, 61-75) were analyzed in the intention-to-treat cohort. Most prevalent ≥grade 3 toxicities included leukopenia (n = 80 [96
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40674676
%R 10.1200/JCO-25-00439
%U https://inrepo02.dkfz.de/record/302998